Coloplast Management

Management criteria checks 4/4

Coloplast's CEO is Kristian Villumsen, appointed in Dec 2018, has a tenure of 5.33 years. total yearly compensation is DKK23.30M, comprised of 51.5% salary and 48.5% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth €11.74M. The average tenure of the management team and the board of directors is 6 years and 6.3 years respectively.

Key information

Kristian Villumsen

Chief executive officer

kr.23.3m

Total compensation

CEO salary percentage	51.5%
CEO tenure	5.3yrs
CEO ownership	0.05%
Management average tenure	6yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kristian Villumsen's remuneration changed compared to Coloplast's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	kr.5b
Sep 30 2023	kr.23m	kr.12m	kr.5b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	n/a	n/a	kr.5b
Sep 30 2022	kr.21m	kr.12m	kr.5b
Jun 30 2022	n/a	n/a	kr.5b
Mar 31 2022	n/a	n/a	kr.5b
Dec 31 2021	n/a	n/a	kr.5b
Sep 30 2021	kr.22m	kr.11m	kr.5b
Jun 30 2021	n/a	n/a	kr.5b
Mar 31 2021	n/a	n/a	kr.4b
Dec 31 2020	n/a	n/a	kr.4b
Sep 30 2020	kr.20m	kr.11m	kr.4b
Jun 30 2020	n/a	n/a	kr.4b
Mar 31 2020	n/a	n/a	kr.4b
Dec 31 2019	n/a	n/a	kr.4b
Sep 30 2019	kr.17m	kr.10m	kr.4b
Jun 30 2019	n/a	n/a	kr.4b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	n/a	n/a	kr.4b
Sep 30 2018	kr.11m	kr.6m	kr.4b
Jun 30 2018	n/a	n/a	kr.4b
Mar 31 2018	n/a	n/a	kr.4b
Dec 31 2017	n/a	n/a	kr.4b
Sep 30 2017	kr.10m	kr.6m	kr.4b

Compensation vs Market: Kristian's total compensation ($USD3.35M) is below average for companies of similar size in the German market ($USD5.57M).

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.

CEO

Kristian Villumsen (53 yo)

5.3yrs

Tenure

kr.23,300,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kristian Villumsen	President & CEO	5.3yrs	kr.23.30m	0.045% DKK 11.7m
Anders Lonning-Skovgaard	Executive VP & CFO	9.8yrs	kr.11.90m	0.0012% DKK 307.4k
Allan Rasmussen	Executive Vice President of Global Operations	9.8yrs	kr.10.50m	0% DKK 0
Nicolai Andersen	Executive Vice President of Innovation	no data	kr.10.00m	no data
Paul Marcun	Executive Vice President of Growth	5.3yrs	kr.12.00m	no data
Thomas Barfod	Senior Controller & Employees Representative Director	no data	kr.450.00k	0.000020% DKK 5.2k
Ellen Bjurgert	Vice President of Investor Relations	7.5yrs	no data	no data
Dennis Kaysen	Director of Corporate Communications	no data	no data	no data
Dorthe Ronnau	Senior Vice President of People & Culture	2.3yrs	no data	no data
Alain Morvan	Senior Vice President of Sales Europe	12yrs	no data	no data
Rasmus Møller	Senior Vice President of Wound & Skin Care	3.6yrs	no data	no data
Manu Varma	Senior Vice President of Chronic Care - North America	6yrs	no data	no data

6.0yrs

Average Tenure

54yo

Average Age

Experienced Management: CBHD's management team is seasoned and experienced (6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Barfod	Senior Controller & Employees Representative Director	18.3yrs	kr.450.00k	0.000020% DKK 5.2k
Carsten Hellmann	Independent Director	6.3yrs	kr.690.00k	0.0027% DKK 695.6k
Lars Rasmussen	Chairman of the Board	5.3yrs	kr.1.84m	0.092% DKK 24.0m
Niels Louis-Hansen	Deputy Chairman	56.3yrs	kr.938.00k	1.93% DKK 502.4m
Marianne Wiinholt	Independent Director	3.3yrs	kr.880.00k	0.00022% DKK 57.3k
Jette Nygaard-Andersen	Independent Director	8.3yrs	kr.600.00k	no data
Nikolaj Gundersen	Employees Representative Director	6.3yrs	kr.450.00k	no data
Roland Pedersen	Employees Representative Director	6.3yrs	kr.450.00k	0.00072% DKK 187.6k
Annette Bruls	Independent Director	2.3yrs	kr.600.00k	no data

6.3yrs

Average Tenure

58yo

Average Age

Experienced Board: CBHD's board of directors are considered experienced (6.3 years average tenure).

Coloplast Management

Management criteria checks 4/4

Key information

Recent management updates

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 21% undervalued after recent price drop

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: €117

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €136

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €128

New 90-day low: €130

New 90-day low - €132

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

New 90-day low - €137

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age